Search results for " Combination"

showing 10 items of 923 documents

Impact of liver steatosis on the antiviral response in the hepatitis C virus-associated chronic hepatitis.

2006

: Background/Aim: Liver steatosis (LS) has been variably associated with chronic hepatitis C (CHC) but whether it affects sustained virological response to antiviral treatment and by what mechanisms is a question still under debate, at least for some genotypes. The aim of this work was to assess the frequency of LS, its relationship with host and viral factors and to what extent it can influence the response to antiviral combination therapy with pegylated interferon (INF)+ribavirin in a group of patients with CHC from a single center. Patients: One hundred and twelve patients with histologically proven CHC were treated with Peg INF-α 2a 180 μg a week subcutaneously for 48 weeks plus ribavir…

AdultMalemedicine.medical_specialtyPathologyAgingCombination therapyGenotypeHepatitis C virusantiviral treatmentHepacivirusInterferon alpha-2Single Centermedicine.disease_causeGastroenterologyAntiviral AgentsSeverity of Illness IndexBody Mass IndexPolyethylene Glycolsliver steatosischemistry.chemical_compoundPegylated interferonInternal medicineGenotypeRibavirinmedicinechronic hepatitis CHumansAspartate AminotransferasesHepatologybusiness.industryRibavirinInterferon-alphaAlanine Transaminasegamma-GlutamyltransferaseHepatitis C ChronicMiddle Agedmedicine.diseaseRecombinant ProteinsFatty LiverTreatment OutcomechemistryLiverDrug Therapy CombinationFemaleSteatosisbusinessBody mass indexmedicine.drugLiver international : official journal of the International Association for the Study of the Liver
researchProduct

Combination treatment with clozapine and paroxetine in schizophrenia: safety and tolerability data from a prospective open clinical trial.

1998

Clozapine is a drug with many side effects, some of them with potentially hazardous outcome (e.g. seizures, agranulocytosis), if not carefully monitored. It has been shown that the metabolism of clozapine may be affected by concomitant treatment with selective serotonin reuptake inhibitors (SSRIs), while there have been reports of improved efficacy on negative symptomatology of clozapine in combination with SSRIs. Therefore, this prospective open clinical trial was performed to investigate the safety and tolerability of the coadministration of clozapine and paroxetine under control of serum concentrations of clozapine and its metabolites and the effect of this combination treatment on psych…

AdultMalemedicine.medical_specialtyPharmacologyPharmacotherapyInternal medicinemedicineHumansPharmacology (medical)Prospective StudiesProspective cohort studyClozapineBiological PsychiatryClozapinePharmacologymedicine.diseaseParoxetineClinical trialPsychiatry and Mental healthParoxetineNeurologyTolerabilitySchizophreniaConcomitantSchizophreniaDrug Therapy CombinationFemaleNeurology (clinical)PsychologySelective Serotonin Reuptake Inhibitorsmedicine.drugAntipsychotic AgentsEuropean neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology
researchProduct

Lack of significant differences between gastrointestinal tract microbial population structure of Helicobacter pylori-infected subjects before and 2 y…

2020

Background According to recent estimates 80% of Latvian population is infected with Helicobacter pylori thus their susceptibility to numerous gastric tract diseases is increased. The 1st line H. pylori eradication therapy includes treatment with clarithromycin in combination with amoxicillin or metronidazole and a proton pump inhibitor. However, potential adverse events caused by such therapies to microbiome are insufficiently studied. Objective This study aimed to evaluate the long-term effect of H. pylori eradication on human gastrointestinal tract (GIT) microbiome. Methods The assessment of H pylori eradication impact on GIT microbiome was done by analyzing 120 samples acquired from 60 s…

AdultMalemedicine.medical_specialtyPopulationGastroenterologyHelicobacter Infections03 medical and health sciences0302 clinical medicineInternal medicineClarithromycinClarithromycinMetronidazolemedicineHumansMicrobiomeeducationeducation.field_of_studybiologybusiness.industryGastroenterologyAmoxicillinProton Pump InhibitorsGeneral MedicineHelicobacter pyloriAmoxicillinMiddle Agedbiology.organism_classificationLatviaAnti-Bacterial AgentsGastrointestinal MicrobiomeMetronidazoleInfectious Diseases030220 oncology & carcinogenesis030211 gastroenterology & hepatologyEnterotypeDrug Therapy CombinationFemaleSample collectionbusinessmedicine.drugHelicobacterREFERENCES
researchProduct

The Effects of Prostaglandin E-1 in Patients with Intermittent Claudication

2006

Aim of the study is to evaluate the effects of Prostaglandin E-1 (PGE-1) in patients with peripheral arterial disease (PAD) at the 2nd b stage Fontaines classification. The study, controlled, single blinded, enrolled 123 patients with intermittent claudication that were randomised in two groups; the first group received a treatment with PGE-1 while the second one received a pentoxifylline-buflomedil association by venous infusion. We evaluated: Pain Free Walking Distance (PFWD), Maximum Walking Distance (MWD), Rest Flow (RF), Peak Flow (PF), Basal (BVR) and Minimal Vascular Resistance (MVR) with a strain gauge plethysmograph, Resting Flow (RF), Peak Flow (PF), time to reach the Peak Flow (t…

AdultMalemedicine.medical_specialtyPyrrolidinesVasodilator AgentsProstaglandinHemodynamicsWalkingSeverity of Illness IndexMicrocirculationchemistry.chemical_compoundInternal medicineLaser-Doppler FlowmetrymedicineHumansPlethysmographAlprostadilPentoxifyllineInfusions IntravenousAgedPharmacologybusiness.industryHematologyGeneral MedicineIntermittent ClaudicationMiddle AgedLaser Doppler velocimetryIntermittent claudicationSurgeryPeripheralPlethysmographyDrug CombinationsTreatment Outcomemedicine.anatomical_structurechemistryRegional Blood FlowExercise TestVascular resistanceCardiologyMolecular MedicineFemaleVascular Resistancemedicine.symptomCardiology and Cardiovascular MedicinebusinessCardiovascular & Hematological Disorders-Drug Targets
researchProduct

Long-term sequential deferiprone-deferoxamine versus deferiprone alone for thalassemia major patients: a randomised clinical trial

2009

A multicentre randomized open-label trial was designed to assess the effectiveness of long-term sequential deferiprone–deferoxamine (DFO–DFP) versus DFP alone to treat thalassaemia major (TM). DFP at 75 mg/kg, divided into three oral daily doses, for 4 d/week and DFO by subcutaneous infusion (8–12 h) at 50 mg/kg per day for the remaining 3 d/week was compared with DFP alone at 75 mg/kg, administered 7 d/week during a 5-year follow-up. The main outcome measures were differences between multiple observations of serum ferritin concentrations. Secondary outcomes were survival analysis, adverse events, and costs. Consecutive thalassaemia patients (275) were assessed for eligibility; 213 of these…

AdultMalemedicine.medical_specialtyRandomizationAdolescentPyridonesAdministration OralKaplan-Meier EstimateDeferoxamineInfusions SubcutaneousIron Chelating AgentsGastroenterologylaw.inventionYoung Adultchemistry.chemical_compoundRandomized controlled triallawInternal medicinemedicineHumansDeferiproneAdverse effectDecreased serum ferritinSurvival analysisbusiness.industryHematologySurgeryClinical trialDeferoxamineChelation thalassaemia clinical trials red blood cell disorders iron overload.Treatment OutcomechemistryFerritinsThalassemiaDrug Therapy CombinationFemalebusinessDeferiproneFollow-Up Studiesmedicine.drug
researchProduct

Efficacy, safety and quality of life of calcipotriol/betamethasone dipropionate (Dovobet (R)) versus calcipotriol (Daivonex (R)) in the treatment of …

2007

Objective: A clinical trial was performed to evaluate the efficacy, speed of response, side effects and quality of life of patients treated with calcipotriol/betamethasone dipropionate (Dovobet (R)) for 4 weeks followed by maintenance with calcipotriol for 8 weeks (group A) versus calcipotriol (Daivonex (R)) alone for 12 weeks (group B) for the treatment of psoriasis. Materials and methods: A total of 150 patients were enrolled and randomized to groups A and B. PASI and Skindex-29 were considered the outcome measures. Results: Ninety-six patients completed the trial. At weeks 2 and 4, both groups showed a significant clinical improvement compared to baseline; group A demonstrated a higher c…

AdultMalemedicine.medical_specialtyRandomizationAdolescentskindex-29medicine.drug_classBetamethasone dipropionatecalcipotriol/betamethasone dipropionate; Dovobet; calcipotriol. Daivonex; psoriasis vulgaris; clinical trialDermatologyAdministration CutaneousBetamethasoneSeverity of Illness IndexDrug Administration Schedulelaw.inventionchemistry.chemical_compoundRandomized controlled trialCalcitriolcalcipotriolo/betametasone dipropionatolawPsoriasisInternal medicinepasimedicineHumansPsoriasiscalcipotriolo; calcipotriolo/betametasone dipropionato; pasi; psoriasi; skindex-29CalcipotriolcalcipotriolopsoriasiAgedAged 80 and overAnalysis of Variancebusiness.industrycalcipotriol calcipotriol/betamethasone dipropionate PASI psoriasis Skindex-29 two-compound productMiddle Agedmedicine.diseaseSurgeryClinical trialDrug CombinationsTreatment OutcomechemistryQuality of LifeCorticosteroidBetamethasoneFemaleDermatologic Agentsbusinessmedicine.drug
researchProduct

Mycophenolate mofetil versus azathioprine in patients with chronic active ulcerative colitis: a 12-month pilot study.

2000

Ulcerative colitis (UC) is an inflammatory bowel disease (IBD) of unknown etiology frequently requiring long-term therapy for control of symptoms and prevention of relapse. Azathioprine (AZA) has been shown to be effective and safe in the treatment of chronic active UC. However, the alternatives to treatment with AZA are limited. Our aim was to compare the efficacy and safety of treatment with mycophenolate mofetil (MMF)/prednisolone versus standard immunosuppressive treatment with azathioprine (AZA)/prednisolone in patients with chronic active UC.The study was designed as an open comparison of MMF versus AZA. Twenty-four patients with active UC (Rachmilewitz scoreor =6 points) were randoml…

AdultMalemedicine.medical_specialtyRandomizationPrednisoloneAzathioprinePilot ProjectsMycophenolateGastroenterologyMycophenolic acidInternal medicineAzathioprineMedicineHumansColitisGlucocorticoidsAgedHepatologybusiness.industryChronic ActiveRemission InductionGastroenterologyMiddle AgedMycophenolic Acidmedicine.diseaseUlcerative colitisSurgeryChronic DiseasePrednisoloneColitis UlcerativeDrug Therapy CombinationFemalebusinessImmunosuppressive Agentsmedicine.drugThe American journal of gastroenterology
researchProduct

A Comparison of Five Maintenance Therapies for Reflux Esophagitis

1995

Patients with reflux esophagitis have a high rate of relapse within one year after therapy is discontinued.We enrolled 175 adults with endoscopy-confirmed reflux esophagitis in a prospective study comparing five maintenance therapies. All the patients were initially treated with omeprazole (40 mg orally once a day) for four to eight weeks, and healing was confirmed by endoscopy. Participants were then stratified according to their initial grade of esophagitis and randomly assigned to 12 months of treatment with one of the following: cisapride (10 mg three times a day), ranitidine (150 mg three times a day), omeprazole (20 mg per day), ranitidine plus cisapride (10 mg three times a day), or …

AdultMalemedicine.medical_specialtyRanitidineSeverity of Illness IndexGastroenterologyDisease-Free SurvivalRanitidinePiperidinesRecurrenceInternal medicinemedicineHumansSingle-Blind MethodProspective StudiesReflux esophagitisProspective cohort studyEsophagitis PepticOmeprazoleCisapridemedicine.diagnostic_testEsophageal diseasebusiness.industryGeneral MedicineMiddle AgedAnti-Ulcer Agentsmedicine.diseaseSurgeryEndoscopyTreatment OutcomeHistamine H2 AntagonistsCisaprideDrug Therapy CombinationFemaleEsophagoscopybusinessEsophagitisOmeprazolemedicine.drugNew England Journal of Medicine
researchProduct

Different doses of consensus interferon plus ribavirin in patients with hepatitis C virus genotype 1 relapsed after interferon monotherapy: a randomi…

2006

AIM: To assess the efficacy of different schedules of consensus interferon (CIFN) plus ribavirin in retreating chronic hepatitis C patients who relapsed after recombinant interferon (rIFN) monotherapy. METHODS: Forty-five patients (34 males and 11 females) with chronic hepatitis due to hepatitis C virus (HCV) genotype 1 who relapsed after a previous course of rIFN monotherapy were randomized to receive 9 μg CIFN three times per week for 52 wk (group A, n = 22) or 18 μg CIFN three times per week for 52 wk (group B, n = 23) in combination with ribavirin 800 to 1200 mg daily for 52 wk (according to body weight). Virological response was evaluated at week 24 (EVR), at the end of treatment (ETR)…

AdultMalemedicine.medical_specialtySettore MED/07 - Microbiologia E Microbiologia ClinicavirusesHepacivirusAlpha interferonHepacivirusPharmacologyGastroenterologyAntiviral AgentsDrug Administration Schedulelaw.inventionchemistry.chemical_compoundRandomized controlled triallawInterferonRecurrenceInternal medicineRibavirinmedicineHumansIn patientSettore MED/12 - GastroenterologiabiologyDose-Response Relationship Drugbusiness.industryRibavirinGastroenterologyInterferon-alphaGeneral MedicineHepatitis C ChronicMiddle AgedViral Loadbiology.organism_classificationhumanitiesRecombinant ProteinsTreatment OutcomechemistryInterferon Type IInterferon Ribavirin Hepatitis C virus Hepatitis C RelapserDrug Therapy CombinationFemalebusinessViral loadInterferon type IRapid Communicationmedicine.drugWorld journal of gastroenterology
researchProduct

Comparison of topical tacrolimus 0.1 % in pectin ointment with clobetasol 0.5% ointment in adults with moderate to severe desquamative gingivitis: A …

2006

BACKGROUND: Desquamative gingivitis (DG) is a clinical condition characterized by red, painful, glazed, and friable gingiva, which might be a manifestation of some autoimmune mucocutaneous diseases. The time from the development of initial signs of DG to diagnosis can vary from months to years. Based on a literature search, no data concerning patients with DG without signs of autoimmune disease were available. OBJECTIVE: The aim of this trial was to compare the efficacy and tolerability of monotherapy with topical tacrolimus 0.1% in pectin ointment versus clobetasol propionate 0.5% ointment in adults affected by DG. METHODS: This randomized, double-blind clinical trial was conducted at the …

AdultMalemedicine.medical_specialtySettore MED/09 - Medicina InternaErythemaAdministration TopicalPopulationSeverity of Illness IndexTacrolimuslaw.inventionOintmentsRandomized controlled trialDouble-Blind Methodlawdesquamative gingivitimedicineClinical endpointHumansPharmacology (medical)educationAgedPharmacologyeducation.field_of_studyDose-Response Relationship Drugbusiness.industryMiddle Agedmedicine.diseaseDermatologyGingivitisdesquamative gingivitisTacrolimusSurgeryDesquamative gingivitisTreatment OutcomeTolerabilityclobetasoltopical tacrolimus; clobetasol; desquamative gingivitis; randomized double-blind clinical trialtacrolimus clobetasol desquamative gingivitisPectinsDrug Therapy CombinationFemaleClobetasol propionatemedicine.symptombusinessImmunosuppressive Agentsmedicine.drugFollow-Up Studiestopical tacrolimurandomized double-blind clinical trial
researchProduct